Iambic Therapeutics
AI-driven discovery for oncology and neurology
Principal Medical Writer
More locations: San Diego, CA, USA
About the job
- A bachelor's degree in a life science or health-related field is required; an advanced master's, PhD, or PharmD degree is preferred.
- A minimum of 10 years of relevant medical writing experience is required.
- Demonstrated experience with Investigational New Drug submissions and documents supporting clinical-stage programs is required.
- Strong scientific writing, communication, and organizational skills are required.
- Highly skilled in the Microsoft Office suite, particularly Microsoft Word.
- A strong understanding of FDA and EMA regulations and International Council for Harmonisation guidelines is required.
- Comfort working and collaborating in a fast-paced environment is required.
- Plan, author, and deliver submission-ready documents, including protocols, investigator brochures, Development Safety Update Reports, clinical study reports, Investigational New Drug submissions, health authority responses, and briefing documents.
- Independently lead cross-departmental document development by collaborating with Clinical, Nonclinical, Medical, Biostatistics, Chemistry, Manufacturing, and Controls, and Regulatory teams.
- Represent medical writing on internal cross-functional study teams and ad hoc working groups.
- Support the development of abstracts, posters, and presentations for scientific conferences.
- Help establish and refine medical writing processes, templates, and standards to ensure consistency, quality, and accuracy across deliverables.
- Implement and manage efficient document workflows and timelines.
- Participate in the evaluation and integration of artificial-intelligence-enabled tools to improve writing quality and efficiency.
- Experience with electronic document and reference management systems.
- Aptitude and interest in learning and adopting new technologies, including artificial-intelligence-enabled tools.
About the company
Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$303M
Headquarters
San Diego, California
Founded
2019
Get referred to Iambic Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Iambic filed an IPO on September 21, 2026, after $207.9 million cash.
- Revenues reached $18 million over the twelve months ended June 30, 2026.
- ClinicalTrials.gov shows IAM1363 recruiting 383 patients across 53 sites, including EU expansion.
What critics are saying
- IAM1363 remains unproven; Phase 1 completion sits in 2028, delaying any approval.
- Iambic's revenue still depends on partnerships; AbbVie and IPO proceeds fund the burn.
- If AbbVie walks and IAM1363 fails, Iambic becomes a platform story without assets.
What makes Iambic Therapeutics unique
- Enchant v3 spans 6,000+ molecular properties across 16 modalities, compressing discovery cycles.
- AbbVie's September 21, 2026 collaboration validates Iambic's platform with another pharma heavyweight.
- IAM1363 reached Phase 1 from AI design, proving platform-to-clinic execution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Company Match
Unlimited Paid Time Off
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -2%2 year growth
↓ -4%AbbVie and Iambic Therapeutics have entered into a multi-year collaboration to accelerate AI-driven drug discovery in immunology, neuroscience, and oncology. The partnership will combine Iambic's molecular superintelligence platform with AbbVie's therapeutic expertise to develop small molecule therapies with first-in-class and best-in-class potential. The collaboration will utilise Enchant v3, Iambic's next-generation multimodal transformer model trained on over 6,000 molecular properties. This technology is designed to optimise candidate properties simultaneously, reducing drug discovery timelines whilst improving success rates. Under the agreement, Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated through the collaboration. The partnership aims to accelerate the discovery process and deliver breakthrough medicines to patients more quickly.
Iambic, a clinical-stage life science and technology company, has launched Enchant v3, the latest version of its AI-driven multimodal transformer model for drug discovery and development. The model features 41 billion parameters and has been pretrained on 4.5 trillion tokens. Enchant v3 can predict more than 6,000 molecular properties across 16 biomedical modalities, including text, assay data, molecule structure, protein structure, images, multi-omics, biologics, clinical trial data, and pharmacokinetics. The system is designed to integrate diverse data sources and improve prediction accuracy as the model scales. Iambic initially launched Enchant in 2024. The company says its platform combines AI with automated chemistry and biology experimentation, and it previously discovered a novel drug candidate that advanced to clinical trials in approximately two years.
Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.
San Diego, CA – Nov. 10, 2025 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.
Iambic Therapeutics has secured over $100 million in a new funding round, as revealed by CEO Tom Miller. The investment comes from ARK and Regeneron, highlighting significant financial backing for the San Diego-based biotech company.